1,3-di-tert-butyl-2-fluoro-5-methylbenzene | 1610366-32-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,3-di-tert-butyl-2-fluoro-5-methylbenzene
• 英文别名: 3,5-di-tert-butyl-4-fluorotoluene；1,3-Ditert-butyl-2-fluoro-5-methylbenzene；1,3-ditert-butyl-2-fluoro-5-methylbenzene
• CAS: 1610366-32-9
• 化学式: C₁₅H₂₃F
• 分子量: 222.346
• InChiKey: LTLBQUFCVUXRAD-UHFFFAOYSA-N

物化性质

• 沸点：
  248.5±9.0 °C(Predicted)
• 密度：
  0.913±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1,3-di-tert-butyl-2-fluoro-5-methylbenzene 在 N-溴代丁二酰亚胺(NBS) 、 potassium carbonate 、 过氧化苯甲酰 作用下， 以 甲醇 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 66.0h， 生成
  参考文献：
  名称：

  Enantioselective Oxidation of Alkenes with Potassium Permanganate Catalyzed by Chiral Dicationic Bisguanidinium

  摘要：

  Chiral anion-controlled ion-pairing catalysis was demonstrated to be a wide-ranging strategy that can utilize a variety of cationic metal species. In a similar manner, we envision a complementary strategy using chiral cation in partnership with inorganic anionic metal salts. Herein, we report a chiral dicationic bisguanidinium-catalyzed asymmetric oxidation reaction of alkenes with potassium permanganate. Chiral induction is attributed to ion-pairing interaction between chiral cation and enolate anion. The success of the current permanganate oxidation reaction together with mechanistic insights should provide inspiration for expansion to other anionic metal salts and would open up new paradigms for asymmetric transition metal catalysis, phase-transfer catalysis, and ion-pairing catalysis.

  DOI：

  10.1021/jacs.5b05792
• 作为产物：
  描述：

  3,5-二叔丁基甲苯 在 Selectfluor 作用下， 以 乙腈 为溶剂， 反应 12.0h， 生成 1,5-di-tert-butyl-2-fluoro-3-methylbenzene 、 1,3-di-tert-butyl-2-fluoro-5-methylbenzene
  参考文献：
  名称：

  Enantioselective Oxidation of Alkenes with Potassium Permanganate Catalyzed by Chiral Dicationic Bisguanidinium

  摘要：

  Chiral anion-controlled ion-pairing catalysis was demonstrated to be a wide-ranging strategy that can utilize a variety of cationic metal species. In a similar manner, we envision a complementary strategy using chiral cation in partnership with inorganic anionic metal salts. Herein, we report a chiral dicationic bisguanidinium-catalyzed asymmetric oxidation reaction of alkenes with potassium permanganate. Chiral induction is attributed to ion-pairing interaction between chiral cation and enolate anion. The success of the current permanganate oxidation reaction together with mechanistic insights should provide inspiration for expansion to other anionic metal salts and would open up new paradigms for asymmetric transition metal catalysis, phase-transfer catalysis, and ion-pairing catalysis.

  DOI：

  10.1021/jacs.5b05792

文献信息

• PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (ROR-GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES
  申请人：Steeneck Christoph

  公开号：US20140142082A1

  公开（公告）日：2014-05-22

  The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administrating these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo sulfonamide compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.

  该发明提供了调节孤儿核受体RORy的调节剂，并通过向需要治疗RORy介导疾病的人类或哺乳动物施用这些新型RORy调节剂的方法进行治疗。具体而言，本发明提供了化合物1的吡咯磺酰胺化合物及其对映体，异构体，互变异构体，溶剂化物和药学上可接受的盐。
• CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA]
  申请人：Phenex Pharmaceuticals AG

  公开号：US20150175562A1

  公开（公告）日：2015-06-25

  The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide or sulfonamide containing cyclic compounds of Formula (1), (1′), (100), (100′), (200) and (200′) and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.

  本发明提供了用于孤儿核受体RORy的调节剂，并通过向需要治疗RORy介导的疾病的人类或哺乳动物注射这些新型RORy调节剂的方法。具体而言，本发明提供了公式（1）、（1'）、（100）、（100'）、（200）和（200'）的含有羧酰胺或磺酰胺的环状化合物及其对映异构体、互异构体、互变异构体、/V-氧化物、溶剂化物和药学上可接受的盐。
• PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORy, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES
  申请人：PHENEX PHARMACEUTICALS AG

  公开号：US20140349987A1

  公开（公告）日：2014-11-27

  The invention provides modulators for the orphan nuclear receptor ROR γ and methods for treating ROR γ mediated diseases by administrating these novel ROR γ modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo carboxamide compounds of Formula (1) and the enantiomers, diastereomers, N-oxides, tautomers, solvates and pharmaceutically acceptable salts thereof.

  该发明提供了用于孤儿核受体RORγ的调节剂，并通过向需要此类治疗的人或哺乳动物中施用这些新型RORγ调节剂的方法来治疗RORγ介导的疾病。具体而言，本发明提供了公式（1）的吡咯羧酰胺化合物及其对映体、二对映异构体、N-氧化物、互变异构体、溶剂化物和药学上可接受的盐。
• CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA
  申请人：PHENEX PHARMACEUTICALS AG

  公开号：US20150344423A1

  公开（公告）日：2015-12-03

  The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide containing cyclic compounds of Formula (1) to Formula (5) and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.

  本发明提供了用于孤儿核受体RORy的调节剂，并通过向需要治疗RORy介导的疾病的人类或哺乳动物施用这些新型RORy调节剂来治疗这些疾病的方法。具体而言，本发明提供了公式（1）至公式（5）的含有羧酰胺的环状化合物及其对映体、二对映异构体、互变异构体、/V-氧化物、溶剂化物和药学上可接受的盐。
• Total Synthesis of a Reported Fluorometabolite from <i>Streptomyces</i> sp. TC1 Indicates an Incorrect Assignment. The Isolated Compound Did Not Contain Fluorine
  作者：Mohammed Salah Ayoup、David B. Cordes、Alexandra M. Z. Slawin、David O’Hagan

  DOI：10.1021/np500260z

  日期：2014.6.27

  3,5-Di-tert-butyl-4-fluorophenylpropionic acid (1) was recently reported as a natural product from Streptomyces sp. TC1. This was a notable disclosure because fluorinated natural products are exceedingly rare, and in this case it suggested that the bacterium had the capacity to mediate an enzymatic aryl fluorination reaction. However, a synthesis of the putative metabolite 1 demonstrates that the spectroscopic data are inconsistent with the proposed structure. There is no evidence that the isolated compound contained a fluorine atom.